AbbVie Inc. R&D Expenses

R&D Expenses of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including R&D Expenses growth rates and interactive chart. Research and development (R&D) expenses are associated with the research and development of a company's goods or services. A company generally incurs R&D expenses in the process of finding and creating new products or services. It is an operating expense and can be deducted from a company's income taxes.


Highlights and Quick Summary

  • R&D Expenses for the quarter ending March 30, 2021 was $1.73 Billion (a -4.94% decrease compared to previous quarter)
  • Year-over-year quarterly R&D Expenses increased by 23.12%
  • Annual R&D Expenses for 2020 was $6.17 Billion (a 14.8% increase from previous year)
  • Annual R&D Expenses for 2019 was $5.38 Billion (a 2.83% increase from previous year)
  • Annual R&D Expenses for 2018 was $5.23 Billion (a 4.43% increase from previous year)
  • Twelve month R&D Expenses ending March 30, 2021 was $6.53 Billion (a 5.69% increase compared to previous quarter)
  • Twelve month trailing R&D Expenses decreased by -1.19% year-over-year
Trailing R&D Expenses for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$6.53 Billion $6.18 Billion $5.9 Billion $6.61 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical R&D Expenses of AbbVie Inc.

Most recent R&D Expensesof ABBV including historical data for past 10 years.

Interactive Chart of R&D Expenses of AbbVie Inc.

AbbVie Inc. R&D Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $1,731.0
2020 $1,821.0 $1,575.0 $1,406.0 $1,379.0 $6,173.0
2019 $1,542.0 $2,285.0 $1,291.0 $1,289.0 $5,377.0
2018 $6,495.0 $1,268.0 $1,322.0 $1,244.0 $5,229.0
2017 $1,408.0 $1,228.0 $1,229.0 $1,142.0 $5,007.0
2016 $1,209.0 $1,106.0 $1,124.0 $946.0 $4,226.0
2015 $1,075.0 $1,418.0 $981.0 $811.0 $4,285.0
2014 $879.0 $812.0 $834.0 $772.0 $3,297.0
2013 $798.0 $714.0 $709.0 $634.0 $2,855.0
2012 $681.0 $813.0 $642.0 $642.0 $2,778.0
2011 $2,602.91 $0.0 $0.0 $587.1 $2,618.0
2010 $2,495.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.